1. Extensor Digitorum Brevis and DIRECTION: Two Studies in Progress Comparing the Duration of Response of AbobotulinumtoxinA With Other Native Botulinum Toxins. (July 2022) Authors: Esquenazi, Alberto; Pons, Laurent; Calvi-Gries, Françoise; Otto, James Journal: Toxicon Issue: Volume 214(2022)Supplement 1 Page Start: S16 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Factors Associated With Favorable Response in Real-World Use of Botulinum Toxin Type A Products for Adult Patients With Upper Limb Spasticity. (July 2022) Authors: Jacinto, Jorge; Ashford, Stephen; Fheodoroff, Klemens; Danchenko, Natalya; Calvi-Gries, Françoise; Bourhis, Yann; Whalen, John; Turner-Stokes, Lynne Journal: Toxicon Issue: Volume 214(2022)Supplement 1 Page Start: S26 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Final Analysis of a Real-World, Retrospective Study in the United Kingdom Evaluating Treatment Outcomes of AbobotulinumtoxinA in Adult Focal Spasticity. (July 2022) Authors: Gaid, Moheb; Brown, Caroline; Bains, Manjinder; Calvi-Gries, Françoise; Degtiar, Vadim; Orridge, Samantha Journal: Toxicon Issue: Volume 214(2022)Supplement 1 Page Start: S19 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Predictors of HbA1c over 4 years in people with type 2 diabetes starting insulin therapies: The CREDIT study. Issue 3 (June 2015) Authors: Balkau, Beverley; Calvi-Gries, Françoise; Freemantle, Nick; Vincent, Maya; Pilorget, Valerie; Home, Philip D. Journal: Diabetes research and clinical practice Issue: Volume 108:Issue 3(2015) Page Start: 432 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗